Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming presentations at the ...
Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.
6d
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Bra ...
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners’ Global Healthcare Conference to outline its strategy around “next-generation RAS therapeutics,” highlighting thre ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 23, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...
Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the ...
Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused ...
9d
NMR reveals site-specific structural signatures of therapeutic antibodies without isotope labeling
Monoclonal antibodies are widely used to treat diseases ranging from cancer to autoimmune disorders. The safety and efficacy ...
MiNK Therapeutics collaborates with C-Further to advance PRAME-targeted iNKT cell therapy for paediatric cancer: New York Thursday, March 12, 2026, 10:00 Hrs [IST] MiNK Therapeuti ...
Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results